Poster
Quizartinib
EHA 2026 | June 11 - 14, 2026
Hematology
Quality-adjusted time without symptoms or toxicity of quizartinib vs placebo in patients with newly diagnosed FLT3-ITD+ acute myeloid leukemia in the QuANTUM-First trial
Jorge Cortes
Poster
Quizartinib
EHA 2026 | June 11 - 14, 2026
Hematology
Quizartinib with reinduction chemotherapy and as single-agent maintenance in children and adolescents with relapsed/refractory FLT3-ITD+ AML: A phase 1/2 multicenter study
C. Michel Zwaan